80 related articles for article (PubMed ID: 11021744)
1. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
Zalupski MM; Philip PA; LoRusso P; Shields AF
Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Bookman MA; Creasman WT
Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
[TBL] [Abstract][Full Text] [Related]
9. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Mazumdar M; Icasiano E; Higgins G; Herr H; Bajorin DF
Invest New Drugs; 2000 Aug; 18(3):247-51. PubMed ID: 10958593
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S
Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.
Ramaswamy B; Mrozek E; Kuebler JP; Bekaii-Saab T; Kraut EH
Invest New Drugs; 2011 Apr; 29(2):347-51. PubMed ID: 19844661
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
Plaxe SC; Blessing JA; Morgan MA; Carlson J;
Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
[TBL] [Abstract][Full Text] [Related]
17. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
Small EJ; Fippin LJ; Whisenant SP
Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
Lynch G; Currie V; Kemeny N
Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
